Edition:
United Kingdom

Aquestive Therapeutics Inc (AQST.OQ)

AQST.OQ on NASDAQ Stock Exchange Global Market

6.85USD
8:00pm GMT
Change (% chg)

$0.27 (+4.10%)
Prev Close
$6.58
Open
$6.58
Day's High
$6.86
Day's Low
$6.56
Volume
4,369
Avg. Vol
34,934
52-wk High
$19.80
52-wk Low
$5.60

Latest Key Developments (Source: Significant Developments)

Aquestive Therapeutics Granted Temporary Restraining Order Against Alvogen
Friday, 25 Jan 2019 

Jan 25 (Reuters) - Aquestive Therapeutics Inc ::AQUESTIVE THERAPEUTICS GRANTED TEMPORARY RESTRAINING ORDER (TRO) AGAINST ALVOGEN.AQUESTIVE THERAPEUTICS - TRO TO REMAIN IN PLACE PENDING HEARING ON PRELIM. INJUNCTION MOTION PREVIOUSLY FILED BY CO, INDIVIOR.AQUESTIVE THERAPEUTICS - TRO ENJOINS ALVOGEN FROM INITIATING ANY LAUNCH ACTIVITIES RELATED TO ITS GENERIC BUPRENORPHINE/NALOXONE SUBLINGUAL FILM.AQUESTIVE THERAPEUTICS INC - HEARING ON PI MOTION IS SCHEDULED WITH DISTRICT COURT ON FEBRUARY 7, 2019.  Full Article

Aquestive Therapeutics Launches Sympazan Oral Film With Widespread U.S. Availability
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - Aquestive Therapeutics Inc ::AQUESTIVE THERAPEUTICS LAUNCHES SYMPAZAN™ (CLOBAZAM) ORAL FILM WITH WIDESPREAD U.S. AVAILABILITY.  Full Article

Aquestive Therapeutics Gets Tentative FDA Approval For Sympazan (Clobazam) Oral Film
Friday, 31 Aug 2018 

Aug 31 (Reuters) - Aquestive Therapeutics Inc ::AQUESTIVE THERAPEUTICS ANNOUNCES TENTATIVE FDA APPROVAL FOR SYMPAZAN (CLOBAZAM) ORAL FILM.SAYS FINAL FDA APPROVAL FOR SYMPAZAN PENDING EXPIRATION OF ORPHAN DRUG EXCLUSIVITY PERIOD FOR ONFI, EXPECTED IN OCT.  Full Article

FDA declines to approve Aquestive's Viagra rival

Nov 16 Aquestive Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve its erectile dysfunction treatment and sought additional data.